Drug Profile

EgyVax vaccine - Eva Pharma

Alternative Names: COVID-2019 vaccine - Eva Pharma

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eva Pharma; Ministry of Higher Education and Scientific Research; Supreme Council of University Hospitals, Egypt
Developer Eva Pharma
Class COVID-19 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Mar 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Egypt (IM, Injection)
06 Feb 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in Egypt (IM) (NCT05218070)
01 Feb 2022 Eva Pharma plans the phase I Sphinx trial for COVID-2019 infections (Prevention) in Egypt (IM,Injection) in March 2022 (NCT05218070)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com